E
75.87
-0.57 (-0.75%)
| Previous Close | 76.44 |
| Open | 76.62 |
| Volume | 5,346,320 |
| Avg. Volume (3M) | 3,831,981 |
| Market Cap | 44,543,279,104 |
| Price / Earnings (TTM) | 41.92 |
| Price / Earnings (Forward) | 29.24 |
| Price / Sales | 8.10 |
| Price / Book | 4.71 |
| 52 Weeks Range | |
| Earnings Date | 22 Apr 2026 |
| Profit Margin | 75.71% |
| Operating Margin (TTM) | 29.01% |
| Diluted EPS (TTM) | 2.42 |
| Quarterly Revenue Growth (YOY) | 6.20% |
| Quarterly Earnings Growth (YOY) | 1.70% |
| Total Debt/Equity (MRQ) | 6.86% |
| Current Ratio (MRQ) | 4.45 |
| Operating Cash Flow (TTM) | 876.20 M |
| Levered Free Cash Flow (TTM) | 1.45 B |
| Return on Assets (TTM) | 8.42% |
| Return on Equity (TTM) | 16.51% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Medical Devices (US) | Mixed | Bearish |
| Medical Devices (Global) | Mixed | Bearish | |
| Stock | Edwards Lifesciences Corporatio | Bullish | Bullish |
AIStockmoo Score
1.4
| Analyst Consensus | 5.0 |
| Insider Activity | -3.5 |
| Price Volatility | -1.0 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | 4.0 |
| Average | 1.40 |
|
Spun off from Baxter International in 2000, Edwards Lifesciences designs, manufactures, and markets a range of medical devices and equipment for advanced stages of structural heart disease. It has established itself as a leader across key products, including surgical tissue heart valves, transcatheter aortic valves, and transcatheter mitral and tricuspid valve technologies. The firm derives about 60% of its total sales from outside the US. |
|
| Sector | Healthcare |
| Industry | Medical Devices |
| Investment Style | Mid Growth |
| % Held by Insiders | 0.91% |
| % Held by Institutions | 89.29% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 110.00 (Stifel, 44.99%) | Buy |
| Median | 100.00 (31.80%) | |
| Low | 87.00 (Canaccord Genuity, 14.67%) | Hold |
| 87.00 (Baird, 14.67%) | Hold | |
| Average | 97.54 (28.56%) | |
| Total | 9 Buy, 4 Hold | |
| Avg. Price @ Call | 82.34 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| BTIG | 11 Feb 2026 | 103.00 (35.76%) | Buy | 79.33 |
| Goldman Sachs | 11 Feb 2026 | 95.00 (25.21%) | Buy | 79.33 |
| Piper Sandler | 11 Feb 2026 | 100.00 (31.80%) | Buy | 79.33 |
| 20 Jan 2026 | 98.00 (29.17%) | Buy | 83.46 | |
| Truist Securities | 11 Feb 2026 | 89.00 (17.31%) | Hold | 79.33 |
| Wells Fargo | 11 Feb 2026 | 100.00 (31.80%) | Buy | 79.33 |
| Stifel | 20 Jan 2026 | 110.00 (44.98%) | Buy | 83.46 |
| 07 Jan 2026 | 105.00 (38.39%) | Buy | 84.83 | |
| Barclays | 12 Jan 2026 | 104.00 (37.08%) | Buy | 83.01 |
| 08 Dec 2025 | 103.00 (35.76%) | Buy | 84.32 | |
| UBS | 12 Jan 2026 | 95.00 (25.21%) | Hold | 83.01 |
| TD Cowen | 09 Jan 2026 | 97.00 (27.85%) | Buy | 85.13 |
| JP Morgan | 18 Dec 2025 | 100.00 (31.80%) | Buy | 84.80 |
| Canaccord Genuity | 17 Dec 2025 | 87.00 (14.67%) | Hold | 84.84 |
| Baird | 16 Dec 2025 | 87.00 (14.67%) | Hold | 85.32 |
| Citigroup | 11 Dec 2025 | 101.00 (33.12%) | Buy | 84.24 |
| Show more | ||||
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| BOBO DONALD E JR | - | 85.29 | -35,340 | -2,990,221 |
| DAHL ANDREW M. | - | 79.78 | -176 | -14,041 |
| LIPPIS DANIEL J. | - | 79.78 | -432 | -34,465 |
| Aggregate Net Quantity | -35,948 | |||
| Aggregate Net Value ($) | -3,038,727 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | 82.54 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| BOBO DONALD E JR | Officer | 02 Mar 2026 | Automatic sell (-) | 11,340 | 87.18 | 988,621 |
| BOBO DONALD E JR | Officer | 02 Mar 2026 | Option execute | 11,340 | - | - |
| BOBO DONALD E JR | Officer | 25 Feb 2026 | Sell (-) | 24,000 | 83.40 | 2,001,600 |
| DAHL ANDREW M. | Officer | 22 Feb 2026 | Disposed (-) | 176 | 79.78 | 14,041 |
| LIPPIS DANIEL J. | Officer | 22 Feb 2026 | Disposed (-) | 432 | 79.78 | 34,465 |
| Date | Type | Details |
|---|---|---|
| 03 Feb 2026 | Announcement | Edwards Lifesciences to Host Earnings Conference Call on February 10, 2026 |
| 02 Feb 2026 | Announcement | Edwards Lifesciences to Present at the TD Cowen 46th Annual Health Care Conference |
| 09 Jan 2026 | Announcement | Edwards Comments on JenaValve Acquisition |
| 23 Dec 2025 | Announcement | FDA Approves Edwards Lifesciences' SAPIEN M3 Mitral Valve Replacement System as First Transseptal Transcatheter Therapy |
| 18 Dec 2025 | Announcement | Edwards Lifesciences to Present at the 44th Annual J.P. Morgan Healthcare Conference |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |